Brief: Milestone Pharmaceuticals Reports Q1 2023 Financial Results, Provides Clinical And Corporate Update

Milestone Pharmaceuticals

11/05/2023 12:56

May 11 (Reuters) - Milestone Pharmaceuticals Inc
 MIST.O :
    * MILESTONE PHARMACEUTICALS REPORTS FIRST QUARTER 2023
FINANCIAL
RESULTS AND PROVIDES CLINICAL AND CORPORATE UPDATE
    * NDA SUBMISSION FOR ETRIPAMIL IN PATIENTS WITH PSVT
CURRENTLY ON
TRACK FOR 3Q23
    * MILESTONE PHARMACEUTICALS - CASH RESOURCES AS OF MARCH 31,
,
TOGETHER WITH STRATEGIC MARCH 2023 FINANCING, EXPECTED TO FUND
OPERATIONS INTO MID-2025
    * TOPLINE DATA FROM PHASE 2 REVERA STUDY EVALUATING
ETRIPAMIL IN
PATIENTS WITH AFIB-RVR EXPECTED IN H2, 2023
    * AS OF MARCH 31, 2023, MILESTONE HAD CASH, CASH
EQUIVALENTS, AND
SHORT-TERM INVESTMENTS OF $101.0 MILLION
    * QTRLY LOSS PER SHARE $0.35
    * Q1 EARNINGS PER SHARE VIEW $-0.40 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nCNW8q7kKa 
Further company coverage:  MIST.O 

 ((Reuters.Briefs@thomsonreuters.com;))